Bomi Italia : 28-10-2016 BOMI ITALIA S.P.A. - BOMI GROUP ANNOUNCES THE ACQUISITION OF BERGA S.R.L.

- PRESS RELEASE -

With its fifth consecutive acquisition in Italy, Bomi Group continues the strategy of diversifying its areas of competency and expanding its core business, by directly investing in a company that offers strategic positioning in the heart of the biomedical district of Mirandola.

The transaction envisages an enterprise value in terms of equity value of about Euro 425,000. In 2015 the company has realized a turnover of about 750,000 €, with net profit of about Euro 110,000 and a positive net financial position.

Giorgio Ruini, Chairman of Bomi Italia S.p.A., noted the following about the transaction: "Today the Group takes another step in its growth strategy, by merging with a company that has worked for many years with companies in the Mirandola biomedical district, which is considered a centre of excellence for this sector. The transaction concluded today contributes to strengthening Bomi Group's position in Italy in the sector of transport, storage and logistics of medical devices and pharmaceuticals, while at the same time offering significant opportunities in the dynamic area of exports, which distinguishes the Mirandola district at a global level." Mauro Gavioli, Director and Sole Shareholder of Berga S.r.l., added his own comment on the transaction: "We are pleased to become part of the prestigious Bomi Group."

Bomi Italia S.p.A. is the holding company of Bomi Group, a leader in biomedical logistics and management of advanced technology health products. The Company is among the first to have obtained the "Elite" certificate from Borsa Italiana.

Bomi Group's activities are focused in the segment of integrated logistics, offering a wide range of logistical services in outsourcing to healthcare companies, managing, specifically, medical devices, pharmaceuticals, products for in vitro diagnostics, reagents and implantable products.

The Bomi Group has a portfolio of more than 100 customers, including the most important global players in the healthcare sector (such as leading pharmaceutical companies and manufacturers of medical devices), as well as small and medium-sized companies in the biomedical, diagnostics and biotech sector at a global level. Currently, the Group has approximately 1,000 employees and a presence, through subsidiaries and investee companies, in Europe, South America and the United States. Its services are provided in various countries, including China, through strategic alliances with local partners.

ISIN Code for ordinary shares: IT0005108748 - Ordinary shares ticker: BOMI

ISIN Code for convertible bonds: IT0005114480 - Convertible bonds ticker: BOMI20

For more information: